CN115734782A - 用于预防或治疗病毒性阴道周边部疾病的医药组合物 - Google Patents

用于预防或治疗病毒性阴道周边部疾病的医药组合物 Download PDF

Info

Publication number
CN115734782A
CN115734782A CN202180045812.6A CN202180045812A CN115734782A CN 115734782 A CN115734782 A CN 115734782A CN 202180045812 A CN202180045812 A CN 202180045812A CN 115734782 A CN115734782 A CN 115734782A
Authority
CN
China
Prior art keywords
pharmaceutical composition
vaginal
compound
nonionic surfactant
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180045812.6A
Other languages
English (en)
Chinese (zh)
Inventor
小野木博
山口哲夫
佐藤克彦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KinoPharma Inc
Original Assignee
KinoPharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KinoPharma Inc filed Critical KinoPharma Inc
Publication of CN115734782A publication Critical patent/CN115734782A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A61K9/025—Suppositories; Bougies; Bases therefor; Ovules characterised by shape or structure, e.g. hollow layered, coated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202180045812.6A 2020-10-28 2021-02-19 用于预防或治疗病毒性阴道周边部疾病的医药组合物 Pending CN115734782A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020-180339 2020-10-28
JP2020180339 2020-10-28
PCT/JP2021/006418 WO2022091442A1 (ja) 2020-10-28 2021-02-19 ウイルス性腟周辺部疾患の予防又は治療のための医薬組成物

Publications (1)

Publication Number Publication Date
CN115734782A true CN115734782A (zh) 2023-03-03

Family

ID=81382191

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180045812.6A Pending CN115734782A (zh) 2020-10-28 2021-02-19 用于预防或治疗病毒性阴道周边部疾病的医药组合物

Country Status (11)

Country Link
US (1) US20230398107A1 (https=)
EP (1) EP4238565B1 (https=)
JP (1) JP7606239B2 (https=)
KR (1) KR20230098175A (https=)
CN (1) CN115734782A (https=)
CA (1) CA3199945A1 (https=)
ES (1) ES3045576T3 (https=)
PL (1) PL4238565T3 (https=)
TW (1) TWI890738B (https=)
WO (1) WO2022091442A1 (https=)
ZA (1) ZA202304812B (https=)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009020198A1 (ja) * 2007-08-03 2009-02-12 Kinopharma, Inc. 抗ｄｎａウイルス作用を有するアニリン誘導体
WO2010095494A1 (ja) * 2009-02-19 2010-08-26 アサヒビール株式会社 難溶性物質を含有する顆粒、錠剤、及び難溶性物質の可溶化方法
JP2015048315A (ja) * 2013-08-30 2015-03-16 旭化成ケミカルズ株式会社 セルロース系核粒子及びその製造方法
CN114126590B (zh) * 2019-04-25 2024-01-05 富士制药工业股份有限公司 医药制剂及其制造方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63275519A (ja) * 1987-05-06 1988-11-14 Taisho Pharmaceut Co Ltd 難溶性薬物含有顆粒の製造方法
JP2001081031A (ja) 1999-08-30 2001-03-27 Schering Ag 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
JP2007517062A (ja) 2003-12-29 2007-06-28 アルザ・コーポレーシヨン 機械的圧縮中に付着抵抗を与える薬物顆粒のコーティング
WO2020218517A1 (ja) * 2019-04-25 2020-10-29 富士製薬工業株式会社 医薬製剤およびその製造方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009020198A1 (ja) * 2007-08-03 2009-02-12 Kinopharma, Inc. 抗ｄｎａウイルス作用を有するアニリン誘導体
WO2010095494A1 (ja) * 2009-02-19 2010-08-26 アサヒビール株式会社 難溶性物質を含有する顆粒、錠剤、及び難溶性物質の可溶化方法
JP2015048315A (ja) * 2013-08-30 2015-03-16 旭化成ケミカルズ株式会社 セルロース系核粒子及びその製造方法
CN114126590B (zh) * 2019-04-25 2024-01-05 富士制药工业股份有限公司 医药制剂及其制造方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AZLINDA ANWAR等: ""The kinase inhibitor SFV785 dislocates dengue virus envelope protein from the replication complex and blocks virus assembly"", 《PLOS ONE》, vol. 6, no. 8, 17 August 2011 (2011-08-17), pages 23246 *
ERIKO SUMI等: ""Safety and Plasma Concentrations of a Cyclin-dependent Kinase 9 (CDK9) Inhibitor, FIT039, Administered by a Single Adhesive Skin Patch Applied on Normal Skin and Cutaneous Warts"", 《 CLINICAL DRUG INVESTIGATION》, vol. 39, no. 1, 31 January 2019 (2019-01-31), pages 55 - 61 *
MAKOTO YAMAMOTO等: ""CDK9 inhibitor FIT-039 prevents replication of multiple DNA viruses"", <THE JOURNAL OF CLINICAL INVESTIGATION>, vol. 124, no. 8, 31 August 2014 (2014-08-31), pages 3479 - 3788 *
陆丹玉等: "《药物制剂技术》", vol. 2, 31 August 2018, 江苏凤凰科学技术出版社, pages: 174 - 175 *

Also Published As

Publication number Publication date
WO2022091442A1 (ja) 2022-05-05
JP7606239B2 (ja) 2024-12-25
KR20230098175A (ko) 2023-07-03
EP4238565C0 (en) 2025-09-24
PL4238565T3 (pl) 2025-12-22
ES3045576T3 (en) 2025-11-28
EP4238565A4 (en) 2024-10-09
CA3199945A1 (en) 2022-05-05
EP4238565A1 (en) 2023-09-06
JPWO2022091442A1 (https=) 2022-05-05
EP4238565B1 (en) 2025-09-24
TW202216142A (zh) 2022-05-01
TWI890738B (zh) 2025-07-21
US20230398107A1 (en) 2023-12-14
ZA202304812B (en) 2024-08-28

Similar Documents

Publication Publication Date Title
WO2010012131A1 (zh) 含有莪术油的药物组合物的制药用途
US11213544B2 (en) Application of alginic acid sulfate in preparation of drugs and health care products for preventing and treating diseases caused by human papilloma viruses
CN102670588B (zh) 鞣花酸用于制备抗病毒药物的应用
US20240148729A1 (en) Lopinavir and ritonavir for the treatment of cervix disorders
JP2021525263A (ja) 処置
KR20220106777A (ko) 약제학적 조성물
CN103599093B (zh) 一种抗hpv药物制剂及用途
CN111686084A (zh) 一种盐酸小檗碱谷维素片剂在治疗糖尿病中的应用
CN115734782A (zh) 用于预防或治疗病毒性阴道周边部疾病的医药组合物
HK40083240A (en) Pharmaceutical composition for preventing or treating viral perivaginal disease
KR20210114962A (ko) 류코트리엔 수용체 길항제를 함유하는 신규 제제
US8044098B2 (en) Use of hydroxybenzoic acids and their esters and analogues for preventing or treating virus infection
WO2020077819A1 (zh) 白头翁皂苷b4抗急性痛风性关节炎的医药用途
WO2020088364A1 (zh) 一种用于抗病毒感染的药物组合物及制备方法
WO2025160227A1 (en) Advantageous compounds for treatment of hpv infection and hpv-induced neoplasia
CN115813912A (zh) 海恩酮在制备防治非洲猪瘟药物中的用途
WO2025147598A1 (en) Device system and use for hpv infection and cervical intraepithelial neoplasia
WO2017194031A1 (zh) 蛋白功能抑制剂dapt在制备治疗肿瘤的药物中的用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40083240

Country of ref document: HK